MHRA orders Class 3 recall of Napralief 250mg batches
→Pharmacy supply teams must quarantine recalled Napralief batches now
Change
UK's MHRA ordered a Class 3 recall of three Napralief 250mg batches (B51496, B51497, B51102) over missing safety and dosage information.
Why it matters
Affected packs omit the maximum-three-tablets-per-day instruction and lack warnings on visual disturbances, allergic reactions and blood-test guidance. Stock must return to suppliers and not be dispensed.
Implications
- → Pharmacy supply teams must immediately stop dispensing the recalled batches — continued supply breaches MHRA recall instructions.
- → Pharmacy inventory teams must immediately quarantine batches B51496, B51497, and B51102 — failure risks accidental patient supply from on-hand stock.
Unlock the full brief.
Implications — what this change may force you to review
Who is affected — which people, workflows, or obligations are touched
What to watch — dates, deadlines, and triggers that matter next
Real-time alerts — delivered when a decision-forcing change is published
Clarify with AI — ask what this change means for you
Start free trial
No credit card · $29/month after trial · Active in seconds
Source
View on UK Government